Rheumatic and musculoskeletal disorders induced by immune checkpoint inhibitors: Consequences on overall survival - 05/06/21
, Benjamin Batteux b, c, d, Zuzana Saidak e, f, Claire Poulet g, Jean-Philippe Arnault h, Bruno Chauffert i, Alice Séjourné c, iBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 8 |
| Iconographies | 1 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objectives |
Immune checkpoint inhibitors (ICIs) frequently induce immune related adverse events (irAEs) that may be associated with more favorable clinical outcomes. We aimed to evaluate the impact of all types of rheumatic adverse events (AEs) on overall survival (OS) and tumor response in patients treated with ICIs.
Methods |
We performed a single-center retrospective observational study to analyze the OS and tumor response in patients receiving ICIs who experienced a rheumatic AE compared to those who did not experience any AE.
Results |
From December 2010 to September 2018, 264 patients with any cancer type were included. Forty-three patients (16.3%) presented with at least one rheumatic AE. The median OS of patients with rheumatic AEs was significantly higher than that of patients without AEs, with 132 weeks (95% CI [69.3-not reached]) and 42.7 weeks (95% CI [25.6-not reached]), respectively (P<0.01). This result remained significant after multivariate analysis (HR 0.54, 95% CI [0.30-0.97], P<0.05). Also, tumor response was better in patients with rheumatic AEs.
Conclusion |
The occurrence of rheumatic AEs in patients treated with ICIs is associated with better survival and tumor response. Therefore, it seems essential to detect rheumatic AEs as early as possible to allow rapid and optimal management, given the long-term response potential of these patients.
Le texte complet de cet article est disponible en PDF.Keywords : Arthritis, Autoimmunity, Biomarkers, Immunotherapy, T Lymphocytes
Plan
Vol 88 - N° 4
Article 105168- juillet 2021 Retour au numéro
Article précédent
- Epidemiology of cutaneous involvement in Sjögren syndrome: Data from three French pSS populations (TEARS, ASSESS, diapSS)
- Camille Villon, Laure Orgeolet, Anne-Marie Roguedas, Laurent Misery, Jacques-Eric Gottenberg, Divi Cornec, Sandrine Jousse-Joulin, Raphaele Seror, Jean-Marie Berthelot, Philippe Dieude, Jean-Jacques Dubost, Anne-Laure Fauchais, Vincent Goeb, Eric Hachulla, Pierre-Yves Hatron, Claire Larroche, Gilles Hayem, Véronique Le Guern, Aleth Perdriger, Jacques Morel, Olivier Vittecoq, Xavier Mariette, Valérie Devauchelle-Pensec, Alain Saraux
- The DIGICOD cohort: A hospital-based observational prospective cohort of patients with hand osteoarthritis – methodology and baseline characteristics of the population
- Jérémie Sellam, Emmanuel Maheu, Michel D. Crema, Amel Touati, Alice Courties, Sophie Tuffet, Alexandra Rousseau, Xavier Chevalier, Bernard Combe, Maxime Dougados, Bruno Fautrel, Margreet Kloppenburg, Jean-Denis Laredo, Damien Loeuille, Anne Miquel, François Rannou, Pascal Richette, Tabassome Simon, Francis Berenbaum
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?